Aprea Therapeutics Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2025. The company posted a net loss of $3.2 million, or $0.53 per basic share, compared to a net loss of $3.5 million, or $0.58 per basic share, in the same period of 2024. Operating losses decreased to $3.4 million from $3.8 million in the second quarter of 2024. Research and Development expenses were down to $1.9 million from $2.6 million in the previous year, attributed primarily to reduced study start-up activities and personnel costs. General and Administrative expenses also saw a reduction, amounting to $1.6 million compared to $1.9 million in the prior year, mainly due to lower professional fees and personnel costs. As of June 30, 2025, Aprea reported $16.5 million in cash and cash equivalents. The company highlighted early evidence of disease control in its ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts using their WEE1 inhibitor, APR-1051. Additionally, their macrocyclic ATR inhibitor ATRN-119 showed early activity with seven patients achieving stable disease, including three with significant tumor shrinkage at the 550 mg twice daily dose.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-011149), on August 12, 2025, and is solely responsible for the information contained therein.
Comments